The MIDD has welcomed Steve Weitman as new member. Dr. Weitman was the AT&T Distinguished Chair for Drug Development at the University of Texas Health Science Center at San Antonio and is currently enjoying his retirement in Wisconsin.

He obtained his MD and PhD at the Medical College of Wisconsin. Dr. Weitman is a Pediatric Hematology/Oncologist with about 30 years of experience in cancer drug development. Steve was Professor (with tenure) and Director of the Institute for Drug Development as well as the AT&T Distinguished Chair for Drug Development at the University of Texas Health Science Center at San Antonio. He was previously Chief Medical Officer, Senior Vice President, and Member of the Executive Committee at ILEX Oncology where he led ILEX’s successful development of clofarabine (Clolar™) and guided that product through a successful ODAC and FDA approval. He also worked on the FDA approval of pralatrexate and romidepsin as well as the post-approval commitments for campath. A major focus of his research has been on the transition of new compounds from laboratory to human Phase I studies. As a member of the MIDD, he supports academic drug discovery research at UWM with his expertise and industry connections.